About Shionogi
About Shionogi
Message from Top Management
Brand Statement
Shionogi's Strength
Management Philosophy
Company Profile
Management Strategy
Operations
Compliance
Group Companies
Corporate Governance
Policies
History
Sustainability
Sustainability
Material Issues (Materiality)
Address the problem of antimicrobial resistance (AMR)
Environment
Society
Governance
Access to Healthcare
Stakeholder Engagement
Annual Report / Integrated Report / Environment Report
Data
External Evaluation
About United Nations Global Compact
Information related to infectious diseases
Innovation
Innovation
R&D
IP Strategy
Partnering
Pipeline
Wastewater-based Epidemiology Surveillance Service
News
Investors
Investors
Top Message
Latest IR Information
IR Library
Management Policy
Shareholder Information
Individual Investors
Sustainability
Financial Highlights
IR Calendar
Contact Us
Careers
Search
English
Worldwide
HOME
News
News
Back number
Please select
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
January
Jan.24, 2023
Release
Shionogi to Announce Personnel Reassignment
Jan.17, 2023
Release
Initiation of a Phase1/2/3 Clinical Trial (Part 2) and Phase 3 Additional Dose Clinical Trial in Japanese Pediatric Subjects of the COVID-19 Recombinant Protein-based Vaccine, S-268019
Jan.04, 2023
Release
New Drug Application of Ensitrelvir Fumaric Acid, a Therapeutic Drug for COVID-19 Accepted for Review in South Korea
